- Rigel Pharmaceuticals Provides Business Update
- Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
- Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
- Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
- Rigel to Present at the Jefferies Virtual London Healthcare Conference
- Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
Rigel Pharmaceuticals Inc (RIGLD:DEU) closed at 3.10, -23.27% below its 52-week high of 4.04, set on Jul 14, 2020.
1.14Mar 19 20204.04Jul 14 2020
Markit short selling activity
|Market cap||604.77m USD|
|EPS (TTM)||-0.1648 |
Data delayed at least 15 minutes, as of Jan 15 2021 20:52 GMT.